Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536544 | 0.83 | LTA4H (0.58) | TTRLTA4HHRH1TSHRCYP2C9 | |
| SCHEMBL7648320 | 0.83 | HRH1 (0.41) | TTRLTA4HCAMK2AHRH1TSHR | |
| SCHEMBL15345849 | 0.83 | HRH1 (0.49) | TTRLTA4HCAMK2AHRH1RHEB | |
| SCHEMBL7852798 | 0.83 | HRH1 (0.41) | TTRLTA4HCAMK2AHRH1TSHR | |
| SCHEMBL7861077 | 0.82 | CAMK2A (0.60) | TTRCAMK2ACYP2C9HIF1A | |
| SCHEMBL4447070 | 0.80 | HRH1 (0.64) | LTA4HHRH1SLC6A4 | |
| SCHEMBL7650237 | 0.80 | HRH1 (0.42) | TTRLTA4HCAMK2AHRH1TSHR | |
| SCHEMBL7859967 | 0.80 | PLA2G10 (0.47) | TTRCAMK2ACYP2C9HIF1A | |
| SCHEMBL4454379 | 0.79 | FFAR1 (0.38) | TTRLTA4HCAMK2AHRH1TSHR | |
| SCHEMBL30874042 | 0.79 | MAPT (0.49) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | US | disclosed |
| US-7355079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-08 | — | — | US | disclosed |
| US-7321065-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321065-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321065-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1625111-A4 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20060035980-A1 | Thyronamine derivatives and analogs and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-02-16 | — | — | US | disclosed |
| EP-1625111-A2 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050096485-A1 | Thyronamine derivatives and analogs and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-05-05 | — | — | US | disclosed |
| WO-2004093800-A2 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | TPO, TSHR, THRB | TTR 67/4885LTA4H 1070/4885CAMK2A 2570/4885 |
| US-20060035980-A1 | Thyronamine derivatives and analogs and methods of use thereof | TPO, TSHR, THRB | TTR 59/4885LTA4H 1059/4885CAMK2A 2478/4885 |
| US-20050096485-A1 | Thyronamine derivatives and analogs and methods of use thereof | TPO, TSHR, THRB | TTR 67/4885LTA4H 1070/4885CAMK2A 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.